about kinex
Kinex is a specialty pharmaceutical company focused on the development and commercialization of next generation therapies for cancer and immunomodulatory diseases.
Our Company >>clinical trials
Kinex plans to enter multiple Phase 2 studies with KX01 in 2013. Clinical studies will include Acute Myeloid Leukemia (AML), and Chronic Myeloid Leukemia (CML).
Clinical Trials >>News/Events
Kinex Announces that the US FDA Allows their IND to Begin KX02 Clinical Trials
Tuesday, June 4th, 2013
Kinex Pharmaceuticals, Inc. announced today, that the FDA has allowed its Investigational New Drug (IND) application for KX02, Kinex’s dual src/pretubulin inhibitor
Kinex Pharmaceuticals and Zenith Technology Corporation Announce the Execution of a Collaborative Licensing Agreement
Monday, May 6th, 2013
Kinex Pharmaceuticals and Zenith Technology Corporation, through its affiliate ZenRx, announced today the execution of a collaborative licensing agreement granting Zenith Technology


